Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Adeoye Olukotun Sells 10,000 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Adeoye Olukotun sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the sale, the director owned 33,600 shares in the company, valued at $2,273,376. The trade was a 22.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $69.83 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $9.49 billion, a P/E ratio of -872.77 and a beta of 1.28. The stock has a 50-day moving average price of $49.81 and a 200-day moving average price of $32.05. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $72.36.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter worth about $29,000. Virtus Advisers LLC purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $34,000. Salomon & Ludwin LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,308 shares during the period. Finally, Federated Hermes Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $52,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ARWR has been the topic of several research reports. Bank of America lifted their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. The Goldman Sachs Group lifted their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Piper Sandler lifted their price objective on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $61.89.

Key Stores Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Company-scheduled investor activity in January could be a near-term catalyst: a KOL webinar on Jan 6 that will feature interim clinical data for obesity programs ARO?INHBE and ARO?ALK7, plus a presentation at the J.P. Morgan Healthcare Conference on Jan 12. Favorable interim data or a well-received JPM presentation could boost sentiment. Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
• Neutral Sentiment: Trading activity is below the stock’s average volume today, which can mute short-term moves; fundamental balance-sheet metrics remain strong (high current/quick ratios). No corporate guidance or major deals were announced.
• Negative Sentiment: Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC filings and covered by press. Insider sales can be interpreted negatively by some investors even though the CEO retains a very large position (millions of shares) and reported reductions were small percentage changes in holdings. See SEC filings and press coverage for details. CEO Form 4 Director Form 4 Director Form 4 Director Form 4 Press: Insider Selling

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.